ADMA Biologics (ADMA) - Stock Price & Dividends

ADMA Biologics, Inc. is a biopharmaceutical company that focuses on developing, manufacturing, and selling specialty plasma-derived biologics globally. Their products are designed to address immune deficiencies and infectious diseases in the United States and other parts of the world.

One of the key products offered by ADMA Biologics is BIVIGAM, which is an intravenous immune globulin (IVIG) product specifically created for the treatment of primary humoral immunodeficiency (PI). They also provide ASCENIV, another IVIG product targeted for the treatment of PI, as well as Nabi-HB, used in the treatment of acute exposure to blood that contains the Hepatitis B surface antigen and other related exposures to Hepatitis B.

In addition to their existing product line, ADMA Biologics is actively developing a range of plasma-derived therapeutics, with a focus on combating infections such as S. pneumonia through innovative immunoglobulin treatments. They are committed to advancing methods for treating and preventing various infections throughout their product pipeline.

ADMA Biologics also operates source plasma collection facilities and distributes their products through various channels including independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. Since its inception in 2004, the company has been headquartered in Ramsey, New Jersey. For more information, you can visit their official website at https://www.admabiologics.com.